When I established the ASA Biopharm Safety Monitoring Working group in 2015 (with Bill Wang), one of the first things that we did (with Susan Duke and Mac Gordon) was
The Four Pillars of Advanced Safety Analytics Read More »
US and EU regulators have been strengthening requirements for aggregate safety assessments throughout clinical development. For example, Reference Safety Information in the IB should be restricted to serious adverse reactions
A Call For Alignment: US and EU Safety Reporting Requirements Read More »
The FDA is replacing its current annual reporting requirement for INDs with a more comprehensive and informative FDA Development Safety Update Report (FDA DSUR), which is described in FDA’s ICH
FDA DSUR: Plans are Nothing; Planning is Everything Read More »
March 1, 2023ASAP Process will be joining the Panel at the following events this year. See Our Full List of Upcoming Events UPCOMING 2023Tues, June 28th Operationalizing FDA Medical Queries
